Alector Inc.

This study tested the safety and effects of an experimental drug called AL001 in people who carry genetic mutations that cause frontotemporal dementia. The drug was given intravenously to 33 participants over nearly two years to see how their bodies handled it and to measure cert…

This study tested whether an investigational drug called AL002 could slow the progression of early Alzheimer's disease. 356 participants with early-stage Alzheimer's received either the drug or a placebo via intravenous infusion over 96 weeks. Researchers measured changes in memo…